Rimegepant 75 mg for Migraine

Phase-Based Progress Estimates
Migraine+1 More
Rimegepant - Drug
All Sexes
What conditions do you have?

Study Summary

This study is being conducted to evaluate the efficacy and tolerability of rimegepant for migraine prophylaxis in adults with a history of inadequate response to oral preventive medications

Eligible Conditions
  • Migraine

Treatment Effectiveness

Effectiveness Progress

3 of 3
This is further along than 93% of similar trials

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: Week 1 to 12 of DBT Phase

Week 1
Compare the efficacy of rimegepant (75 mg) to placebo

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Trial Design

2 Treatment Groups

Rimegepant 75 mg
1 of 2
1 of 2

Experimental Treatment

Non-Treatment Group

600 Total Participants · 2 Treatment Groups

Primary Treatment: Rimegepant 75 mg · Has Placebo Group · Phase 4

Rimegepant 75 mg
Experimental Group · 1 Intervention: Rimegepant · Intervention Types: Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: week 1 to 12 of dbt phase

Who is running the clinical trial?

Biohaven Pharmaceuticals, Inc.Lead Sponsor
46 Previous Clinical Trials
31,589 Total Patients Enrolled
13 Trials studying Migraine
14,208 Patients Enrolled for Migraine

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Migraine attacks present for more than 1 year with the age of onset prior to 50 years of age.
You have 4 to 14 migraine days per month, on average, across the 3 months prior to the Screening Visit.
Subjects must be able to distinguish migraine attacks from tension/cluster headaches.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 27th, 2021

Last Reviewed: November 9th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.